What Are Myeloid Disorders and How Are They Treated?

Myeloid disorders are a group of blood cancers and related conditions in which the bone marrow produces abnormal myeloid cells, the lineage that normally gives rise to red blood cells, most white blood cells, and platelets. They range from slow-growing conditions that cause chronic fatigue and low blood counts to aggressive leukemias that demand immediate treatment. The umbrella covers several distinct diseases, each with its own biology and treatment strategy, but all trace back to the same root problem: something goes wrong in the production line that turns stem cells into functioning blood cells.

How Normal Blood Cell Production Goes Wrong

Your bone marrow is constantly churning out billions of blood cells a day through a tightly regulated process. Stem cells at the top of the hierarchy divide and gradually commit to becoming specific cell types. Myeloid progenitors mature into red blood cells (which carry oxygen), platelets (which help blood clot), and several types of white blood cells that fight infection, including neutrophils and monocytes. Myeloid disorders arise when genetic mutations disrupt this maturation process, causing cells to multiply uncontrollably, fail to mature properly, or both.¹

The specific mutation and the stage at which maturation stalls determine which disorder develops. A mutation that locks immature cells (called blasts) in a rapidly dividing state leads to acute myeloid leukemia. A mutation that allows cells to mature but removes the normal brakes on their proliferation leads to a myeloproliferative neoplasm. And mutations that cause cells to mature poorly, producing defective blood cells that die before they can do their job, lead to myelodysplastic syndromes. These categories are not perfectly sealed off from one another; some conditions can evolve into others over time, particularly the slower-growing ones that can transform into acute leukemia.

The Main Types of Myeloid Disorders

Clinicians generally group myeloid disorders into four broad categories, each with a different pace, prognosis, and treatment philosophy.

Acute myeloid leukemia (AML): The most aggressive. Immature blast cells accumulate rapidly in the bone marrow and spill into the bloodstream, crowding out healthy cells. Without treatment, AML can be fatal within weeks to months. It is the most common acute leukemia in adults.
Myelodysplastic syndromes (MDS): A group of conditions in which the bone marrow produces defective blood cells. Patients typically present with low blood counts, fatigue, and increased infection risk. MDS can remain relatively stable for years or progress to AML.²
Myeloproliferative neoplasms (MPNs): Conditions in which the marrow overproduces one or more blood cell types. The three classic MPNs are polycythemia vera (too many red blood cells), essential thrombocythemia (too many platelets), and myelofibrosis (scarring of the marrow). These tend to be chronic but carry risks of blood clots, organ enlargement, and progression to more severe disease.
Chronic myeloid leukemia (CML): Sometimes classified under MPNs, CML is driven by a very specific genetic abnormality and follows a distinct clinical course. It progresses slowly through phases and has been transformed by targeted therapy.

There are also overlap categories, including conditions that share features of both MDS and MPNs, such as chronic myelomonocytic leukemia (CMML). Classification has gotten more granular in recent years, with both the World Health Organization and an international consensus group publishing updated systems that lean heavily on genetic findings rather than just how cells look under a microscope.³

What Causes Myeloid Disorders

Most myeloid disorders arise from acquired genetic mutations, meaning they develop during a person’s lifetime rather than being inherited from a parent. Some of these mutations are now well characterized. The JAK2 V617F mutation, for instance, gives blood cell precursors a growth and survival advantage and is found in the vast majority of polycythemia vera cases and a significant share of other MPNs.⁴ CML is driven by the Philadelphia chromosome, a specific swap of genetic material between chromosomes 9 and 22 that creates the BCR-ABL fusion gene, an overactive signaling protein that drives white blood cell overproduction.⁵

In AML and MDS, the genetic picture is often more complex, with multiple mutations cooperating to drive the disease. Common culprits include mutations in genes like FLT3, NPM1, IDH1, IDH2, TP53, and DNMT3A, each of which has different implications for prognosis and treatment selection. Risk factors for developing a myeloid disorder include older age, prior chemotherapy or radiation for another cancer, and exposure to certain chemicals like benzene. Therapy-related myeloid neoplasms are a recognized category, arising as a late complication of treatment for an earlier malignancy, solid organ transplant, or autoimmune disease.⁶

Researchers have also identified a precursor state called clonal hematopoiesis, in which blood stem cells acquire mutations that give them a competitive edge but have not yet caused a full-blown disorder. Certain features, such as carrying high-risk mutations, having more than one mutation, or having a large clone size, increase the likelihood that clonal hematopoiesis will eventually progress to a myeloid cancer.⁷ This precursor state is increasingly common with age and is an active area of research for early detection strategies.

How Myeloid Disorders Are Diagnosed

Diagnosis typically begins with a complete blood count that reveals abnormal numbers or types of blood cells. A bone marrow biopsy follows, which allows pathologists to examine the marrow directly, assess the percentage of blast cells, and look for signs of abnormal maturation. In MDS, the hallmark is dysplasia, meaning blood cells that look abnormal under the microscope and do not function properly. MDS is separated from AML by a blast threshold: when blasts reach a certain level (traditionally around 20% of marrow cells), the diagnosis shifts to AML.⁸

Genetic testing has become central to diagnosis and is no longer optional for most myeloid disorders. Cytogenetic analysis (looking at whole chromosomes) and molecular testing (sequencing specific genes) together determine which subtype a patient has, which profoundly affects both prognosis and the choice of treatment. In AML, the European Leukemia Network uses genetic findings to assign patients to favorable, intermediate, or adverse risk groups, and these categories guide whether a patient should receive standard chemotherapy alone or proceed to a stem cell transplant.⁹

After initial treatment, monitoring for residual disease has become a powerful way to predict relapse. Techniques like flow cytometry and next-generation sequencing can detect tiny amounts of remaining leukemia cells that are invisible on a standard bone marrow exam. In patients with AML heading into a stem cell transplant, residual disease detected by either method before the transplant significantly increases the risk of relapse afterward.¹⁰

Treating Acute Myeloid Leukemia

AML treatment depends heavily on two factors: the patient’s fitness level and the genetic profile of the leukemia. For younger, fitter patients, the backbone of initial therapy remains intensive induction chemotherapy, a regimen colloquially known as “7+3” because it combines seven days of one drug with three days of another. This regimen has been in use for decades, though the specific doses have been refined over time.¹¹ A randomized trial comparing standard and higher-dose versions found complete remission rates around 85 to 90% after induction, with three-year overall survival in the range of 58 to 65%, and no clear advantage to the higher dose.¹²

For older adults or those with significant health problems who cannot tolerate intensive chemotherapy, the standard of care has shifted toward a combination of venetoclax (a drug that promotes cancer cell death) with a hypomethylating agent. Response rates with this combination are wide-ranging, from roughly 40 to 90%, and three-year survival spans from near zero in patients with unfavorable genetics to around two-thirds for those with favorable mutations like NPM1 or IDH2.¹³ The enormous range underscores how much the genetic subtype of the leukemia drives outcomes.

After achieving remission, the next question is how to keep the disease from coming back. For patients at intermediate or high risk of relapse, an allogeneic stem cell transplant, using donor cells, is often the best option. Transplant adds an immune-mediated attack on remaining leukemia cells (the graft-versus-leukemia effect) that chemotherapy alone cannot provide.¹⁴ Reduced-intensity conditioning regimens have extended transplant access to older patients who would not have tolerated the full-dose preparatory chemotherapy used in earlier decades. In one study of high-risk AML and MDS patients who received a reduced-intensity transplant, the three-year overall survival was about 41%, with a transplant-related death rate of 9% at 100 days.¹⁵

Targeted Therapies and the Shift Away from One-Size-Fits-All

The biggest change in AML treatment over the past decade has been the arrival of drugs that target specific genetic mutations. FLT3 mutations, found in roughly a quarter of AML cases, can now be treated with inhibitors like gilteritinib and quizartinib, both of which showed better response rates than standard salvage chemotherapy in patients whose disease had returned.¹⁶ IDH1 and IDH2 inhibitors (ivosidenib, enasidenib, olutasidenib) target metabolic mutations and achieve overall response rates of 30 to 94% in patients carrying those mutations. Menin inhibitors are a newer class targeting AML with specific gene rearrangements or NPM1 mutations, with response rates in early trials of 33 to 88%.¹⁶

These targeted drugs are increasingly used in combination with venetoclax-based regimens rather than as single agents. For unfit patients, the treatment algorithm now looks more like a decision tree: test for mutations first, then layer on the appropriate targeted inhibitor alongside the backbone regimen. This approach represents a genuine shift from the era when the same chemotherapy was given to everyone regardless of genetics.

One complication worth knowing about is differentiation syndrome, a potentially serious inflammatory reaction that occurs when targeted drugs force leukemia cells to suddenly mature. It is most common with IDH inhibitors (occurring in roughly 10 to 19% of treated patients) and menin inhibitors (10 to 25%), and less frequent with FLT3 inhibitors (1 to 5%).¹⁶ Symptoms can include fever, fluid retention, and breathing difficulties. It is manageable when caught early, typically with corticosteroids, but requires awareness from both the care team and the patient.

Chronic Myeloid Leukemia and the Targeted Therapy Success Story

CML stands as the most dramatic success story in myeloid disorder treatment. The disease is driven by a single well-defined abnormality: the BCR-ABL fusion protein produced by the Philadelphia chromosome, a translocation that swaps pieces of chromosomes 9 and 22.¹⁷ That protein acts as a permanently switched-on growth signal.¹⁸

Tyrosine kinase inhibitors (TKIs), drugs that block the BCR-ABL protein, transformed CML from a disease with poor survival into one where patients can expect a near-normal lifespan.¹⁹ Multiple generations of TKIs are now available, and the treatment philosophy has evolved beyond just keeping patients alive to asking whether some patients can safely stop taking their medication altogether. Trials of treatment-free remission have found that roughly 40 to 60% of carefully selected patients who have achieved a deep and sustained molecular response can discontinue their TKI without the disease returning.²⁰ For those who do relapse after stopping, the reassuring finding is that nearly all respond promptly when the TKI is restarted, and progression to advanced disease is rare.²¹

Treatment-free remission is not an option for every CML patient. Eligibility is currently limited to those who have been on a TKI for years and have maintained a very deep molecular response, meaning the BCR-ABL transcript is barely detectable or undetectable by sensitive testing. Still, the very existence of this option, stopping a cancer drug and staying cancer-free, was unthinkable for CML patients a generation ago. It also addresses the real-world burden that lifelong TKI use creates: side effects like fatigue, muscle cramps, and fluid retention, along with significant financial cost.

Treating Myelodysplastic Syndromes

MDS treatment depends on risk. Lower-risk MDS, where life expectancy is measured in years and the main problems are low blood counts, is often managed with supportive care: transfusions for anemia, growth factors to boost blood cell production, and monitoring. The challenge with chronic transfusions is iron overload, since each unit of red blood cells deposits iron that the body has no efficient way to excrete. Iron chelation therapy becomes important for patients who accumulate a significant transfusion burden.²²

Higher-risk MDS, where there is a substantial chance of progression to AML, is treated more aggressively. Hypomethylating agents like azacitidine are the standard first-line therapy for patients who are not candidates for transplant, and they have improved outcomes compared to older supportive-care-only approaches. However, survival remains poor for transplant-ineligible patients with intermediate- to high-risk disease. Researchers are exploring combinations to do better, such as pairing azacitidine with luspatercept, a drug originally developed for lower-risk MDS anemia, in a modified dosing schedule that appears to reduce side effects like severe drops in blood counts and infections while maintaining effectiveness.²³ For younger, fitter MDS patients with high-risk disease, an allogeneic stem cell transplant remains the only potentially curative option.

Managing Myeloproliferative Neoplasms

The myeloproliferative neoplasms, especially polycythemia vera and essential thrombocythemia, are often chronic conditions that people live with for years or decades. The immediate goal of treatment is to reduce the risk of blood clots, which are the leading cause of serious complications. For polycythemia vera, first-line treatment historically involves phlebotomy (regularly drawing blood to keep the red blood cell count in check) and low-dose aspirin, with hydroxyurea added for higher-risk patients.

This approach, while effective at controlling blood counts, does not address the underlying clone of mutant cells or the chronic inflammation that drives disease progression. Ruxolitinib, a JAK inhibitor, has shown clear superiority over standard therapy in polycythemia vera: in a randomized trial, it achieved far better control of blood counts, spleen size, and symptoms. The proportion of patients meeting the primary treatment goal was about 21% with ruxolitinib versus 1% with standard therapy, and symptom burden dropped by half or more in about 49% of the ruxolitinib group compared to 5% on standard treatment.²⁴

A newer agent, ropeginterferon alfa-2b, has shown the ability to reduce the size of the JAK2-mutant clone itself, something neither phlebotomy nor hydroxyurea accomplishes effectively. This positions it as a genuinely disease-modifying therapy rather than just a symptom controller.²⁵ The field is moving toward using biomarkers like the size of the mutant clone and markers of inflammation to guide therapy choices, rather than simply aiming for normal-looking blood counts.

Myelofibrosis, the most serious MPN, involves progressive scarring of the bone marrow that eventually leads to severe anemia, massive spleen enlargement, and debilitating symptoms. JAK inhibitors (ruxolitinib and newer agents) help with symptoms and spleen size but do not cure the disease. Stem cell transplant is the only curative option for myelofibrosis, though its risks limit it to younger patients with severe disease.

How Pediatric Myeloid Disorders Differ

Children can develop myeloid disorders, including AML and MDS, but the biology is frequently different from adult disease. Pediatric AML tends to carry distinct chromosomal abnormalities and gene mutations compared to adult AML, which means the same diagnostic labels can mask meaningfully different diseases underneath.²⁶ These biological differences require distinct diagnostic workups, treatment protocols, response assessments, and supportive care strategies.²⁷

Children generally tolerate intensive chemotherapy better than older adults, and pediatric AML cure rates are higher overall. However, certain genetic subtypes that carry a good prognosis in children may behave differently in adults, and vice versa. Pediatric oncologists also weigh long-term side effects more heavily, since a child cured of leukemia will live for decades and may face late effects of treatment including fertility issues, heart damage from chemotherapy, and the risk of therapy-related second cancers.

The Growing Role of Genetic Classification

Across all myeloid disorders, the trend is toward defining diseases by their genetics rather than how cells look under a microscope. The updated classification systems from the World Health Organization and the International Consensus Classification both emphasize recurrent genetic abnormalities as the primary way to categorize AML subtypes, though the two systems differ on some technical points like the minimum blast percentage required for an AML diagnosis.³ TP53 mutations, for example, are now recognized as defining a particularly aggressive entity. In AML patients with complex chromosomal abnormalities, TP53 mutations are present in roughly two-thirds of cases and are associated with poor outcomes.²⁸

This genetic-first approach is not just an academic exercise. It directly changes treatment decisions. A patient with an NPM1 mutation and no FLT3 mutation may do well with chemotherapy alone and avoid a transplant, while a patient with a TP53 mutation faces a grim prognosis with standard approaches and may be better served by a clinical trial. In MDS, the same principle applies: the specific mutations present help determine whether a patient has a smoldering condition that can be watched or one that is likely to transform into AML and needs aggressive intervention. For patients and families, this means that genetic testing at diagnosis is not an optional add-on but the foundation on which the entire treatment plan rests.